Figure 2. Differential enrichment of Aβ and Tau correlate with neuropathological measures.
(A) Detergent insoluble β-amyloid (APP) levels measured by label-free MS quantification correlate with CERAD neuropathological plaque severity scores. (B) Detergent insoluble β-amyloid (APP) levels across individual control (n=5), AsymAD (n=6), MCI (n=11) and AD (n=13) cases. (C) Tau (MAPT) measurements measured by label-free MS quantification correlate with Braak neuropathological measures for aggregated tau. (D) Detergent insoluble β-amyloid (APP) levels across control, AsymAD, MCI and AD cases.